Navigation Links
Noninvasive advanced image analysis could lead to better patient care
Date:7/2/2014

PHOENIX, Ariz. July 2, 2014 Lung cancer patients could receive more precise treatment, and their progress could be better tracked, using a new high-tech method of non-invasive medical imaging analysis, according to a study published today by the journal PLOS ONE.

Genetic changes increasingly are recognized as driving cancer development. But obtaining evidence of these changes usually requires a biopsy, which can be problematic for sensitive regions of the body such as the lungs.

Based on a review of 48 patients with non-small cell lung cancer (NSCLC), the study found that by scanning their tumor cells using "quantitative computed tomography based texture analysis" (QTA), researchers could determine with nearly 90 percent accuracy whether the patient's tumor had a cancer-causing K-ras gene mutation.

The study was led by investigators at the Translational Genomics Research Institute (TGen), the Virginia G. Piper Cancer Center at Scottsdale Healthcare, and Cancer Treatment Centers of America (CTCA).

NSCLC represents more than 85 percent of all lung cancers, which will kill an estimated 159,000 Americans this year, making it the leading cause of cancer-related death. It has a five-year survival rate less than 10 percent.

QTA was shown to be an accurate and non-invasive alternative to surgical biopsy and other invasive means of collecting and analyzing biological samples, the study said. This method of making genomic distinctions may help physicians determine the best type of treatment to administer to each patient.

"The ability to rapidly and non-invasively characterize NSCLC tumors would be a great asset to clinical oncologists," said Dr. Glen Weiss, the study's lead author, Director of Clinical Research and Medical Oncologist at Cancer Treatment Centers of America's Western Regional Medical Center in Phoenix, and a Clinical Associate Professor in TGen's Cancer and Cell Biology Division.

"QTA applied to molecularly defined NSCLC cases may have a broader application to precision medicine by offering a non-invasive way of identifying the best therapies for each patient," said Dr. Weiss.

Dr. Ronald Korn, Medical Director of Scottsdale Healthcare's Virginia G. Piper Cancer Center and the study's senior author, described QTA as a substantial step forward in the use of medical imaging: "Non-invasive characterization of a tumor's molecular features could enhance treatment management. Non-invasive QTA can differentiate the presence of K-ras mutation from pan-wildtype NSCLC."

Dr. Korn also is CEO and Medical Director of Imaging Endpoints, a leading imaging core lab that provides centralized image handling and advanced image interpretations for clinical trials. Through Scottsdale Healthcare Research Institute, and in collaboration with Imaging Endpoints Core Lab, this team has developed one of the only global radiology research laboratories that specializes in rapid detection and assessment of response (also known as the RADAR program).

"Although, more studies are needed to move our RADAR program forward towards routine medical use, our core lab remains focused upon characterizing tumors non-invasively through imaging and then using these technologies to help determine, as soon as possible, whether cancer treatments are working, sometimes within days to weeks after the start of therapy" said Dr. Korn.

Dr. Weiss said future studies using QTA also could help identify other genomic sub-types of NSCLC.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. New clinical trial explores novel noninvasive colon cancer screening test
2. New study evaluates noninvasive technology to determine heart disease
3. Biomarker identification may lead to new noninvasive test for colorectal cancer detection
4. Novel noninvasive therapy prevents breast cancer formation in mice
5. Noninvasive brain control
6. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
7. New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
8. MARC travel awards announced for the AAI 2012 Advanced Course in Immunology
9. Advanced Photon Source and Canadian Light Source strengthen ties
10. Adoption of advanced techniques could propel crop improvement
11. Advanced Membrane Technology V Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 23, 2017  GlobeImmune, Inc. today announced it has ... of 12,835,490 shares of its common stock to NantCell, ... connection with the sale of its common stock, NantCell ... issue to GlobeImmune 200,000 shares, an estimated $2.0 million ... "We are pleased to enter into this strategic agreement ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology: